A real-world study reveals FCN/GCV combination therapy enhances 1-year survival in HHV-6B encephalitis post-CBT, particularly after neutrophil engraftment, compared to monotherapy. Findings underscore the need for tailored antiviral strategies based on hematologic recovery.